1. Therapeutic Plasma Exchange in Multiple Sclerosis Patients with Abolished Interferon-beta Bioavailability.
- Author
-
Giedraitiene N, Kaubrys G, Kizlaitiene R, Bagdonaite L, Griskevicius L, Valceckiene V, and Stoskus M
- Subjects
- Adult, Antibodies, Neutralizing immunology, Biological Availability, Biomarkers metabolism, Female, Humans, Interferon-beta immunology, Male, Middle Aged, Myxovirus Resistance Proteins metabolism, Pilot Projects, Reverse Transcriptase Polymerase Chain Reaction, Interferon-beta pharmacokinetics, Multiple Sclerosis metabolism, Multiple Sclerosis therapy, Plasma Exchange methods, Plasmapheresis methods
- Abstract
Background: Neutralizing antibodies (NAb) to interferon-beta (IFN-β) are associated with reduced bioactivity and efficacy of IFN-β in multiple sclerosis (MS). The myxovirus resistance protein A (MxA) gene expression is one of the most appropriate markers of biological activity of exogenous IFN-β. We hypothesized that therapeutic plasma exchange (TPE) can restore the ability of IFN-β to induce the MxA mRNA expression and that maintenance plasmapheresis can sustain the bioavailability of IFN-β., Material and Methods: Eligible patients underwent 4 primary separate plasma exchange sessions. After the induction TPE sessions, they were transferred to maintenance plasmapheresis. Bioactivity of IFN-β was expressed as in vivo MxA mRNA induction in whole blood using RT-qPCR., Results: Six patients with low IFN-β bioavailability detected by the MxA mRNA response were included. Four patients became biological responders after induction plasmapheresis. In 2 patients an increase of MxA mRNA expression was found, but the values persisted below the cut-off and the patients remained as "poor biological responders". The effect of maintenance plasmapheresis was transient: MxA mRNA expression values reverted to the baseline levels after 1-2 months., Conclusions: Therapeutic plasma exchange is able to restore the bioavailability of IFN-β in the majority of studied patients, but the effect of TPE on the IFN-β bioavailability was transient.
- Published
- 2015
- Full Text
- View/download PDF